Zydus Lifesciences Ltd's Q4FY25 Quarter Results
- 21 May 2025
Result Summary
- Zydus Lifesciences Ltd reported a 6.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 12.7%.
- Its expenses for the quarter were up by 0.0% QoQ and 4.6% YoY.
- The net profit increased 21.4% QoQ and increased 247.9% YoY.
- The earnings per share (EPS) of Zydus Lifesciences Ltd stood at 11.7 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 5690.20 | 5326.60 | 5048.40 | 6.8% | 12.7% |
Total Expenses | 4143.20 | 4142.50 | 3961.30 | 0.0% | 4.6% |
Profit Before Tax | 1547.00 | 1184.10 | 485.80 | 30.6% | 218.4% |
Tax | 321.20 | 179.50 | 137.20 | 78.9% | 134.1% |
Profit After Tax | 1246.10 | 1026.20 | 358.20 | 21.4% | 247.9% |
Earnings Per Share | 11.70 | 10.20 | 2.90 | 14.7% | 303.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Zydus Lifesciences Ltd is a prominent player in the pharmaceutical industry, primarily focused on the development, manufacture, and marketing of a wide range of healthcare products. The company is known for its extensive portfolio of therapeutic products, including generic medicines, active pharmaceutical ingredients, and biologics. Over the years, Zydus Lifesciences has established a significant presence not only in India but also in global markets. The company often engages in research and development to innovate and introduce new products. However, specific recent developments beyond the scope of this report are not available due to the time frame of this data.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), Zydus Lifesciences Ltd reported a total income of ₹5690.20 crores, marking a robust increase of 6.8% from the previous quarter (Q3FY25) and a significant rise of 12.7% from the corresponding quarter in the previous year (Q4FY24). This consistent growth reflects the company's ability to enhance its revenue streams over time. In Q3FY25, the total income was ₹5326.60 crores, while in Q4FY24, it stood at ₹5048.40 crores. This upward trend in revenue highlights the demand for the company's products and its strategic effectiveness in capturing market opportunities.
Profitability
Zydus Lifesciences Ltd experienced substantial profitability growth in Q4FY25, with a profit before tax amounting to ₹1547.00 crores. This represents a quarter-over-quarter increase of 30.6% from ₹1184.10 crores in Q3FY25 and a remarkable year-over-year surge of 218.4% from ₹485.80 crores in Q4FY24. After accounting for tax expenses, the profit after tax in Q4FY25 was ₹1246.10 crores, reflecting a 21.4% increase from the previous quarter's ₹1026.20 crores and a 247.9% increase from ₹358.20 crores in the same quarter last year. This notable increase in profitability is accompanied by a rise in tax obligations, with taxes amounting to ₹321.20 crores in Q4FY25, up 78.9% from Q3FY25 and 134.1% from Q4FY24.
Operating Metrics
Earnings per share (EPS) for Zydus Lifesciences Ltd in Q4FY25 was ₹11.70, demonstrating a 14.7% increase from ₹10.20 in Q3FY25 and a substantial 303.4% increase from ₹2.90 in Q4FY24. This increase in EPS reflects the company's enhanced profitability and efficient management of its equity base. Total expenses for the company in Q4FY25 were ₹4143.20 crores, showing minimal change from ₹4142.50 crores in Q3FY25, indicative of stable cost management. Compared to Q4FY24, the expenses increased by 4.6% from ₹3961.30 crores, suggesting controlled operational expenditure in line with revenue growth. These metrics provide insight into the company's financial health and operational efficiency during the period under review.